1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Loncastuximab Tesirine, Rituximab, Gemcitabine - Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Active not recruiting | ADC Therapeutics S.A. | 440 | 2020-09-16 | 2026-04-28 |
Lymphoma (1) · Lymphoma, Large B-Cell, Diffuse (1)
Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma, B-Cell (1) · Lymphoma, Non-Hodgkin (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Gemcitabine (1) · Oxaliplatin (1) · Rituximab (1) · loncastuximab tesirine (1)
Argentina (1) · Belgium (1) · Brazil (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · France (1) · Hungary (1) · Israel (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1)